# Aptevo Therapeutics (APVO) — Earnings

APVO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/apvo/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$151.20 |
| EPS estimate | −$1,497.60 |
| EPS surprise | +89.90% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 11, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1671584/000095017025106247/apvo-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 11, 2025 | −$1,497.60 | −$151.20 | 89.90% | — | — |
| Q1 2025 | May 15, 2025 | −$1,515.60 | −$1,580.40 | -4.28% | — | — |
| Q4 2024 | Feb 14, 2025 | −$2,790.00 | −$3,218.40 | -15.35% | — | — |
| Q3 2024 | Nov 7, 2024 | −$7,592.40 | −$6,393.60 | 15.79% | — | — |
| Q2 2024 | Aug 8, 2024 | −$25,707.60 | −$22,244.40 | 13.47% | — | — |
| Q1 2024 | May 8, 2024 | −$143,456.40 | −$132,534.00 | 7.61% | — | — |
| Q4 2023 | Mar 5, 2024 | −$263,736.00 | −$178,887.60 | 32.17% | — | — |
| Q3 2023 | Nov 14, 2023 | −$375,091.20 | −$293,040.00 | 21.88% | — | — |
| Q2 2023 | Aug 10, 2023 | −$656,409.60 | −$720,878.40 | -9.82% | — | — |
| Q1 2023 | May 11, 2023 | −$694,504.80 | $152,380.80 | 121.94% | — | — |
| Q4 2022 | Mar 30, 2023 | −$896,702.40 | −$621,244.80 | 30.72% | — | — |
| Q3 2022 | Nov 10, 2022 | −$955,310.40 | −$898,116.61 | 5.99% | — | — |
| Q2 2022 | Aug 11, 2022 | −$779,486.40 | $3,252,942.10 | 517.32% | $3.5M | — |
| Q1 2022 | May 12, 2022 | −$673,992.00 | −$931,867.20 | -38.26% | $3.8M | $3.1M |
| Q4 2021 | Mar 24, 2022 | −$758,973.60 | −$761,904.00 | -0.39% | $3.4M | $3.7M |
| Q3 2021 | Nov 12, 2021 | −$838,094.40 | −$849,816.00 | -1.40% | $3.1M | $3.1M |
| Q2 2021 | Aug 12, 2021 | −$1,172,160.00 | −$1,043,222.40 | 11.00% | $1.4M | $3.1M |
| Q1 2021 | May 11, 2021 | −$980,707.20 | −$1,019,779.20 | -3.98% | $2.4M | $2.4M |
| Q4 2020 | Mar 31, 2021 | −$908,424.00 | −$1,060,804.80 | -16.77% | $2.2M | $2.4M |
| Q3 2020 | Nov 10, 2020 | −$1,201,464.00 | −$1,260,072.00 | -4.88% | $563,667.00 | $1.5M |

## Frequently Asked Questions

### When did Aptevo Therapeutics (APVO) last report earnings?

Aptevo Therapeutics last reported on Aug 11, 2025, covering fiscal Q2 2025.

### Did APVO beat earnings estimates?

Yes. Aptevo Therapeutics reported EPS of −$151.20 for Q2 2025 against a −$1,497.60 estimate — a 89.90% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).